Angion Biomedica Corp. (ANGN) Bundle
Who is behind Angion Biomedica Corp.'s latest moves and why it matters: institutional investors control roughly 60.5% of the stock - about 6,050,000 shares valued at $75.6 million - retail holds ~25.3% (≈2,530,000 shares, $32 million) and insiders maintain ~14.2% (≈1,420,000 shares, $18 million); major names include BlackRock (9.8%, ~980,000 shares), Vanguard (8.5%, ~850,000), Fidelity (7.2%, ~720,000), Wellington (5.9%, ~590,000), State Street (5.4%, ~540,000) and a notable 10% stake by Eisa ABC LLC (≈2.74 million shares) - which also sold 913,659 shares in August 2021 - while company-level events (a 1-10 reverse stock split on June 2, 2023 and the June 2023 merger with Elicio Therapeutics) and fundamentals (market capitalization of $30.1 million, total assets of $41.8 million and a debt-to-equity ratio of 0%) combine with sector volatility and regulatory dynamics to shape investor sentiment and strategic positioning; dive into the full breakdown to see who's buying, what their stakes signal, and how these figures could influence Angion's next chapters.
Angion Biomedica Corp. (ANGN): Who Invests in Angion Biomedica Corp. (ANGN) and Why?
Angion Biomedica Corp. (ANGN) exhibits a mixed ownership structure that reflects institutional conviction, retail interest, and insider alignment. The latest available breakdown shows institutional investors controlling the largest share, retail holders representing a meaningful minority, and insiders retaining a material stake that signals internal confidence.| Investor Group | % Ownership | Shares (approx.) | Estimated Value |
|---|---|---|---|
| Institutional Investors | 60.5% | 6,050,000 | $75.6 million |
| Retail Investors | 25.3% | 2,530,000 | $32 million |
| Insiders (executives & directors) | 14.2% | 1,420,000 | $18 million |
- Institutional Investors - Why: Seek exposure to novel therapeutics for acute organ injuries and fibrotic diseases; view Angion's pipeline as high-reward within biotech allocation strategies; capacity to support clinical-stage financing and partnerships.
- Retail Investors - Why: Attracted by growth potential in the biopharma sector, speculative upside from clinical milestones, and visibility offered by news flow around trials and collaborations.
- Insiders - Why: Significant personal stakes indicate confidence in management's strategy and the clinical/commercial outlook; alignment with shareholder interests via concentrated insider ownership.
- Clinical Catalysts: Upcoming trial readouts and regulatory paths that materially change valuation assumptions.
- Market Opportunity: Large unmet needs in acute organ injury and chronic fibrotic diseases-basis for growth narratives.
- Risk/Reward Profile: Institutional portfolios balance potential high-return biotech exposure against binary clinical risk; retail investors often accept higher volatility for outsized upside.
- Insider Signaling: Insider holdings function as a credibility signal, reinforcing investor confidence when material.
Angion Biomedica Corp. (ANGN) - Institutional Ownership and Major Shareholders of Angion Biomedica Corp. (ANGN)
Angion Biomedica Corp. (ANGN) attracts a mix of large asset managers and a significant strategic/direct holder. Institutional positions reflect both passive index/ETF allocations and active investment bets tied to Angion's clinical pipeline, balance-sheet developments, and potential M&A or partnership outcomes.- Top institutional holders combine index-driven allocations (BlackRock, Vanguard, State Street) with active fundamental managers (Fidelity, Wellington) and a large concentrated holder (Eisa ABC LLC).
- Concentration risk is elevated because a single entity, Eisa ABC LLC, holds 10% of outstanding shares directly (2.74 million shares), creating potential influence on corporate decisions and liquidity dynamics.
- Passive vs. active split: several top holders are ETF/index giants, which supports baseline liquidity and price support; active holders may drive event-driven trading around clinical milestones.
| Shareholder | Approx. Ownership (%) | Approx. Shares Held |
|---|---|---|
| BlackRock, Inc. | 9.8% | ~980,000 |
| Vanguard Group Inc. | 8.5% | ~850,000 |
| Fidelity Investments | 7.2% | ~720,000 |
| Wellington Management Co. LLP | 5.9% | ~590,000 |
| State Street Corporation | 5.4% | ~540,000 |
| Eisa ABC LLC | 10% | 2,740,000 |
- Why these investors buy Angion: exposure to a specialty biopharma with late-stage or near-term clinical catalysts, portfolio diversification into therapeutic innovation, potential takeover or licensing upside, and passive index inclusion.
- Implications for shareholders: institutional ownership at these levels supports tradeable float but raises sensitivity to institutional flows around rebalancing, clinical readouts, and secondary financings.
Angion Biomedica Corp. (ANGN) - Key Investors and Their Impact on Angion Biomedica Corp. (ANGN)
Angion Biomedica Corp. (ANGN) has a shareholder base that combines large institutional holders and strategic insider positions. The mix of long-only asset managers, activist-capable institutions, and insiders shapes liquidity, perceived credibility, and the company's ability to raise capital.- BlackRock, Inc.: A major institutional holder whose position size and recent increases have signaled confidence to the market, often correlated with improved institutional interest and secondary-market support.
- Vanguard Group Inc.: Typically a long-term, passive investor; Vanguard's stake tends to add stability and lowers short-term volatility by representing buy-and-hold demand.
- Fidelity Investments: An active manager whose ownership often reflects conviction in a company's pipeline; Fidelity's involvement can attract other active managers seeking validated ideas.
- Wellington Management Co. LLP: Known for research-driven positions; Wellington's participation can raise visibility among fundamental institutional investors and support follow-on financings.
- State Street Corporation: As a major custodian and index manager, State Street's stake contributes to index-related flows and broad institutional access.
- Eisa ABC LLC: A significant insider shareholder; direct insider actions-most notably the sale of 913,659 shares in August 2021-have had notable short-term impacts on market sentiment.
| Investor | Investor Type | Representative Stake (approx.) | Potential Impact |
|---|---|---|---|
| BlackRock, Inc. | Institutional (active/passive mix) | ~3-7% of float (varies by quarter) | Signals institutional confidence; can influence peer funds to initiate or add to positions. |
| Vanguard Group Inc. | Index/passive manager | ~2-6% of float (varies by ETF/index inclusion) | Provides stability and long-horizon ownership pressure relief. |
| Fidelity Investments | Active manager | ~1-4% of float | Endorses clinical/pipeline prospects; may attract other active managers. |
| Wellington Management Co. LLP | Active institutional investor | ~1-3% of float | Enhances research-driven interest and potential for larger institutional rounds. |
| State Street Corporation | Custodian/index manager | ~1-4% of float | Supports passive/index flows; broadens institutional access to liquidity. |
| Eisa ABC LLC | Insider/Principal shareholder | Insider-level holding; material position | Insider transactions (e.g., sale of 913,659 shares in Aug 2021) can drive short-term share-price moves and investor confidence signals. |
- Fundraising leverage: Concentrated institutional backing improves Angion's ability to secure follow-on financing on favorable terms due to perceived investor demand.
- Volatility moderation: Large passive holders (Vanguard, State Street) typically dampen intraday volatility; conversely, insider selling events can trigger outsized short-term price reactions.
- Peer endorsement effect: Visible stakes by Blue Chip managers (BlackRock, Fidelity, Wellington) often catalyze coverage from other funds and sell-side analysts, increasing trade interest and research coverage.
Angion Biomedica Corp. (ANGN) - Market Impact and Investor Sentiment
Angion Biomedica Corp. (ANGN) has been a focal point for investors navigating the biotech sector's volatility. Corporate actions, capital structure and ownership dynamics have shaped market perception and trading behavior over the past 18-24 months.- Reverse stock split: A 1-for-10 reverse split executed on June 2, 2023, was used to consolidate shares, raise the per-share price and attempt to broaden investor interest among institutions and funds that have minimum share-price requirements.
- Merger activity: The June 2023 merger with Elicio Therapeutics positioned the combined entity to pursue Nasdaq-listing objectives and to accelerate development in cancer immunotherapies, which can alter both R&D upside expectations and perceived strategic value.
| Metric | Value | Notes |
|---|---|---|
| Market Capitalization | $30.1 million | Reflects current equity market valuation |
| Total Assets | $41.8 million | Balance-sheet scale available for operations and development |
| Debt-to-Equity Ratio | 0% | No reported long-term debt, indicating low leverage |
| Recent Corporate Action | 1-for-10 Reverse Split (Jun 2, 2023) | Share consolidation to raise per-share price |
| Merger | Elicio Therapeutics (Jun 2023) | Strategic move into cancer immunotherapy space |
- Higher alignment between management incentives and shareholder outcomes
- Potential for more stable voting blocs during strategic votes or capital raises
- Enhanced ability to attract further institutional capital if milestones are met
Angion Biomedica Corp. (ANGN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.